PPLPHARMA211.99

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹28,134 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt4,558.94,720.35,495.55,495.5
Net Debt4,057.44,331.74,163.84,163.8
Total Debt/Equity0.580.580.670.67
Net Debt/Equity0.510.530.510.51
Total Debt/EBITDA3.813.275.965.96
Net Debt/EBITDA3.393.004.524.12
Interest Coverage (EBIT/Interest)1.021.490.270.27
Total Debt/Total Capital %36.5636.7540.2440.24
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.